Hot Pursuit     08-Jun-23
Zydus Life gets USFDA nod for hypertension drug
Zydus Lifesciences announced that it has received final approval from the United States Food and Drug Administration (USFDA) for Tadalafil tablets.
The said drug is equivalent to reference listed drug, Adcirca tablets. Tadalafil relaxes muscles of the blood vessels and increases blood flow to particular areas of the body. It is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.

The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

According to IQVIA MAT April 2023, Tadalafil tablets USP, 20 mg had annual sales of $61 million in the United States.

As of 31 March 2023, the group now has 369 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit (from continuing operations) tumbled 27.55% to Rs 298.8 crore despite of 31.66% jump in total revenue from operations to Rs 5,010.6 crore in Q4 FY23 over Q4 FY22.

The scrip rose 0.18% to currently trade at Rs 515.95 on the BSE.

Previous News
  Zydus Life jumps on USFDA nod for BP lowering drug
 ( Hot Pursuit - 04-Jul-24   16:28 )
  Zydus receives USFDA approval for Zituvimet™ XR tablets
 ( Corporate News - 19-Jul-24   13:58 )
  Zydus Life gets USFDA nod for Zituvimet XR tablets
 ( Hot Pursuit - 19-Jul-24   11:53 )
  Zydus Lifesciences Ltd drops for fifth straight session
 ( Hot Pursuit - 19-Sep-24   13:35 )
  Zydus enters into exclusive licensing and supply agreement with Viwit
 ( Corporate News - 13-Sep-24   21:09 )
  Zydus acquires 50% stake in Sterling Biotech
 ( Corporate News - 24-Aug-24   11:33 )
  Zydus Lifesciences receives USFDA approval for Azilsartan Medoxomil Tablets
 ( Corporate News - 04-Jul-24   14:54 )
  Zydus Lifesciences fixes record date for buyback of shares
 ( Market Beat - Reports 09-Feb-24   17:03 )
  Zydus Life arm inks pact to acquire 50% stake in Sterling Biotech
 ( Hot Pursuit - 24-Aug-24   13:52 )
  Board of Zydus Lifesciences approves buyback of Rs 600 cr
 ( Corporate News - 09-Feb-24   17:50 )
  Indices trade higher; consumer durable shares rally
 ( Market Commentary - Mid-Session 22-Apr-24   13:37 )
Other Stories
  Avantel Q2 PAT jumps 42% YoY to Rs 23 cr
  05-Oct-24   17:03
  Equitas SFB total deposits jump 29% YoY in Q2 FY25
  05-Oct-24   16:28
  Ujjivan SFB total deposits rises 17% in Q2 FY25
  05-Oct-24   15:34
  L&T Finance retail disbursements jump 12% YoY in Q2 FY25
  05-Oct-24   14:31
  Bandhan Bank records over 21% YoY jump in loan book during Q2 FY25; deposits at Rs 1.42 lakh crore
  05-Oct-24   13:32
  Lupin's Pune-based biotech facility gets 5 observations from US FDA
  05-Oct-24   13:20
  Macrotech Developers pre-sales jumps 21% YoY in Q2 FY25
  05-Oct-24   09:04
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
Back Top